Global Biosimilar Monoclonal Antibodies Market Analysis 2026–2030
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Biosimilar Monoclonal Antibodies Market Projected To Become By 2030 Based On Its 2026 Valuation?
The biosimilar monoclonal antibodies market size has shown substantial growth in recent years. It is anticipated to expand from $10.64 billion in 2025 to $11.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.2%. This historical growth can be ascribed to several factors, including the high cost of originator biologics, the increasing prevalence of chronic and autoimmune diseases, the expiration of patents for major monoclonal antibodies, rising healthcare expenditure, and improving regulatory clarity for biosimilars.
The biosimilar monoclonal antibodies market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $14.58 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period is attributable to several factors, including the expanding pipelines of biosimilars, a growing need for cost-effective biologic therapies, an increase in approvals within emerging markets, innovations in biopharmaceutical production, and favorable government regulations supporting the uptake of biosimilars. Key trends identified for the forecast timeframe encompass the increasing embrace of economical biosimilar monoclonal antibodies, the broader application of biosimilars in treating oncology and autoimmune conditions, enhanced acceptance of biosimilars by both doctors and patients, the broadening of regulatory approvals across international markets, and a heightened emphasis on improving availability of biologic treatments.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp
What Primary Drivers Are Shaping The Development Of The Biosimilar Monoclonal Antibodies Market?
The increasing occurrence of autoimmune conditions is anticipated to drive expansion in the biosimilar monoclonal antibodies market. These disorders involve the immune system erroneously attacking the body’s own tissues and organs. The rise in such diseases largely stems from environmental factors like pollution and chemicals, disturbing immune equilibrium and fostering unusual immune reactions. Biosimilar monoclonal antibodies play a role in combating the growing prevalence of autoimmune diseases by offering cost-effective, efficacious, and readily available targeted treatments that regulate excessive immune responses in patients. For example, data from February 2024, provided by Arthritis Australia, an Australia-based non-profit organization, indicates that in 2025, approximately 212,136 males and 362,137 females are forecast to be affected by rheumatoid arthritis (RA). These figures are projected to climb by 2040, reaching around 280,040 males and 479,828 females. Consequently, the expanding occurrence of autoimmune diseases is a key factor propelling the growth of the biosimilar monoclonal antibodies market.
What Segment Groups Are Identified Within The Biosimilar Monoclonal Antibodies Market?
The biosimilar monoclonal antibodies market covered in this report is segmented –
1) By Type: Biopharmaceuticals, Other Types
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications
Subsegments:
1) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals
2) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics
What Trends Are Advancing Progress In The Biosimilar Monoclonal Antibodies Market?
Leading companies in the biosimilar monoclonal antibody market are actively developing biosimilar variants of monoclonal antibodies. Their objective is to present more economical alternatives to original monoclonal antibody therapies, thereby improving accessibility and reducing costs within healthcare. An intravenous formulation refers to an antibody preparation specifically designed for direct injection into the bloodstream via a vein, enabling a rapid therapeutic impact. For instance, in May 2024, Bio-Thera Solutions, a biopharmaceutical company based in China, alongside Biogen Inc., a US-based biopharmaceutical company, introduced TOFIDENCE (tocilizumab-bavi) in an intravenous formulation within the United States. The U.S. Food and Drug Administration had previously approved TOFIDENCE in September 2023 for addressing moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. Upon its launch, TOFIDENCE is offered in three vial sizes for intravenous infusion: 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL, with subcutaneous formulations slated for subsequent release.
Which Companies Hold Significant Positions In The Biosimilar Monoclonal Antibodies Market?
Major companies operating in the biosimilar monoclonal antibodies market are Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy’s Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.
Read the full biosimilar monoclonal antibodies market report here:
How Does The Biosimilar Monoclonal Antibodies Market Perform Across Major Global Regions?
North America was the largest region in the biosimilar monoclonal antibodies market in 2025. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Biosimilar Monoclonal Antibodies Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3412&type=smp
Browse Through More Reports Similar to the Global Biosimilar Monoclonal Antibodies Market 2026, By The Business Research Company
Biologics Market 2026
https://www.thebusinessresearchcompany.com/report/biologics-market
Pharmaceutical Drugs And Biologics Logistics Market 2026
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
